Current Edition

Acceleron Pharma

Merck refiles $11.5B Acceleron deal with the FTC. But extending regulators’ review time only one benefit

Merck & Co.’s $11.5 billion bid for Acceleron Pharma is hitting a delay just as activist investors threaten to derail the deal altogether. Merck has …

Continue Reading →

Bristol Myers Squibb, after passing on Acceleron, now eyes Aurinia takeout: Bloomberg

It wasn’t long ago that Bristol Myers Squibb ran the numbers on potentially buying Acceleron Pharma, but that deal didn’t come together, and the biotech …

Continue Reading →